🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

109 results for “PRECISION BIOSCIENCES INC” Clear

  1. 1.0mg/kg/day PRAX-562

    PRECISION BIOSCIENCES INC

    Developmental and Epileptic Encephalopathy 1

    phase 3 small molecule active

    1 trial

  2. 18F fluciclovine

    PRECISION BIOSCIENCES INC

    Brain Metastases

    phase 3 small molecule completed

    2 trials

  3. 1mg elsunersen

    PRECISION BIOSCIENCES INC

    Epileptic Encephalopathy

    phase 3 small molecule active

    1 trial

  4. 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks

    PRECISION BIOSCIENCES INC

    Focal Seizure

    phase 3 small molecule active

    1 trial

  5. 40 mg/day vormatrogine for 12 weeks

    PRECISION BIOSCIENCES INC

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  6. 60 mg ulixacaltamide

    PRECISION BIOSCIENCES INC

    Essential Tremor

    phase 3 small molecule active

    1 trial

  7. Early Vasopressin

    PRECISION BIOSCIENCES INC

    Septic Shock

    phase 3 small molecule active

    1 trial

  8. ICT-107

    PRECISION BIOSCIENCES INC

    Glioblastoma Multiforme

    phase 3 mab completed

    2 trials

  9. PRAX-114

    PRECISION BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  10. PRAX-222

    PRECISION BIOSCIENCES INC

    Voltage-gated sodium channel type II alpha subunit (SCN2A) developmental and epileptic encephalopathy (DEE)

    phase 3 small molecule active

    1 trial

  11. PRAX-562

    PRECISION BIOSCIENCES INC

    SCN2A Encephalopathy

    phase 3 small molecule active

    1 trial

  12. PRAX-628, PRAX-628, PRAX-628, PRAX-628

    PRECISION BIOSCIENCES INC

    Focal onset seizures or primary generalized tonic-clonic seizures.

    phase 3 small molecule active

    1 trial

  13. PRAX-628, PRAX-628, Placebo for PRAX-628, PRAX-628

    PRECISION BIOSCIENCES INC

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  14. Placebo for PRAX-628, PRAX-628

    PRECISION BIOSCIENCES INC

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  15. vormatrogine

    PRECISION BIOSCIENCES INC

    Epilepsy, Tonic-Clonic

    phase 3 small molecule active

    1 trial

  16. 10 mg PRAX-114

    PRECISION BIOSCIENCES INC

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  17. 10 mg PRAX-114, 20 mg PRAX-114, and Placebo

    PRECISION BIOSCIENCES INC

    Essential Tremor

    phase 2 small molecule terminated

    1 trial

  18. 100 mg PRAX-944

    PRECISION BIOSCIENCES INC

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  19. 30mg PRAX-628

    PRECISION BIOSCIENCES INC

    Focal Onset Seizure

    phase 2 small molecule active

    1 trial

  20. 60 mg PRAX-114 or 40 mg PRAX-114

    PRECISION BIOSCIENCES INC

    Post-traumatic Stress Disorder

    phase 2 small molecule terminated

    1 trial

  21. Atorvastatin Oral Tablet

    PRECISION BIOSCIENCES INC

    Mild Cognitive Impairment

    phase 2 small molecule active

    1 trial

  22. BCMA CAR-T cells

    PRECISION BIOSCIENCES INC

    Multiple Myeloma

    phase 2 mab active

    2 trials

  23. BCMA targeted prime CAR-T cells

    PRECISION BIOSCIENCES INC

    Multiple Myeloma

    phase 2 mab active

    1 trial

  24. CD123 CAR-T cells

    PRECISION BIOSCIENCES INC

    Leukemia

    phase 2 mab active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources